Affiliation:
1. The Affiliated Anyang Tumor Hospital of Henan University of Science and Technology
Abstract
Abstract
purpose:As part of supportive therapy, prophylaxis with tiopronin for injection (TI) against common hepatotoxicity complications has often been used. However, methods to prevent hepatotoxicity have not been established. Therefore, we analyzed the relationship between the periods of TI prophylaxis and its efficacy in preventing hepatotoxicity,evaluate the value of prolonging the duration of TI administration in preventing hepatotoxicity in gynecological cancer patients.
Methods This is a retrospective study. During 2022.1–2023.3, 452 patients with gynecological cancer patients were included in this study,the patient had normal liver function tests before treatment. The influencing factors of liver toxicity after treatment were analyzed, and different subgroups were divided according to the influencing factors. In total sample and different subgroups, we evaluated the prophylactic efficacy of TI by comparing the number of days of TI use. and the difference of the number of days of TI use on the prognosis of patients was compared in the total samples.
Results In total samples, there was no significant difference the effectiveness of TI with different prevention days for hepatotoxicity (P>0.05), and there was no significant difference in prognosis of tumor (P>0.05). The influencing factors of hepatotoxicity were the combinations of chemotherapeutic drugs,duration of chemotherapy drug use and the previous hepatotoxicity of patients. In different subgroups, there was no significant difference the effectiveness of TI with different prevention days for hepatotoxicity (P>0.05).
Conclusion TI is used as prophylactic drug in gynecological cancers, and prolonging periods of administration has no clinical value in preventing hepatotoxicity.
Publisher
Research Square Platform LLC
Reference30 articles.
1. A heartrending burden of gynaecological cancers in advance stage at nuclear institute of medicine and radiotherapy Jamshoro Sindh[J];Bibi S;Pakistan Journal of Medical Sciences,2016
2. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J];Freddie Bray;CA: a cancer journal for clinicians,2018
3. Cancer statistics in China and United States, 2022: profiles, trends, and determinants [J];Xia C;Chin Med Engl,2022
4. Immunotherapy for Ovarian Cancer: Adjuvant, Combination, and Neoadjuvant;Yang C;Front Immunol[J]. Front Immunol,2020
5. Cervical cancer: A global health crisis[J];Small W;Cancer,2017